Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Operations (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash from Operations for 11 consecutive years, with 26708000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations changed N/A to 26708000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 48605163.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 71500000.0 for FY2025, 129.9% down from the prior year.
  • Cash from Operations for Q4 2025 was 26708000.0 at Crescent Biopharma, down from 16791171.0 in the prior quarter.
  • The five-year high for Cash from Operations was 5105992.0 in Q1 2025, with the low at 26708000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 12371307.06, with a median of 12206712.0 recorded in 2021.
  • The sharpest move saw Cash from Operations plummeted 303.56% in 2021, then skyrocketed 57.03% in 2023.
  • Over 5 years, Cash from Operations stood at 12806565.0 in 2021, then soared by 38.22% to 7911569.0 in 2022, then rose by 3.75% to 7614997.0 in 2023, then tumbled by 38.0% to 10508829.0 in 2024, then crashed by 154.15% to 26708000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 26708000.0, 16791171.0, and 5105992.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.